These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 35955902

  • 1. Multitargeting the Action of 5-HT6 Serotonin Receptor Ligands by Additional Modulation of Kinases in the Search for a New Therapy for Alzheimer's Disease: Can It Work from a Molecular Point of View?
    Czarnota-Łydka K, Kucwaj-Brysz K, Pyka P, Haberek W, Podlewska S, Handzlik J.
    Int J Mol Sci; 2022 Aug 07; 23(15):. PubMed ID: 35955902
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease.
    Benhamú B, Martín-Fontecha M, Vázquez-Villa H, Pardo L, López-Rodríguez ML.
    J Med Chem; 2014 Sep 11; 57(17):7160-81. PubMed ID: 24850589
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Novel 1H-Pyrrolo[3,2-c]quinoline Based 5-HT6 Receptor Antagonists with Potential Application for the Treatment of Cognitive Disorders Associated with Alzheimer's Disease.
    Grychowska K, Satała G, Kos T, Partyka A, Colacino E, Chaumont-Dubel S, Bantreil X, Wesołowska A, Pawłowski M, Martinez J, Marin P, Subra G, Bojarski AJ, Lamaty F, Popik P, Zajdel P.
    ACS Chem Neurosci; 2016 Jul 20; 7(7):972-83. PubMed ID: 27100049
    [Abstract] [Full Text] [Related]

  • 7. Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs.
    Millan MJ, Dekeyne A, Gobert A, Brocco M, Mannoury la Cour C, Ortuno JC, Watson D, Fone KCF.
    Neuropharmacology; 2020 Oct 15; 177():108099. PubMed ID: 32525060
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer's disease.
    Wicke K, Haupt A, Bespalov A.
    Expert Opin Investig Drugs; 2015 Oct 15; 24(12):1515-28. PubMed ID: 26548316
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The procognitive effects of 5-HT6 receptor ligands in animal models of schizophrenia.
    Nikiforuk A.
    Rev Neurosci; 2014 Oct 15; 25(3):367-82. PubMed ID: 24501158
    [Abstract] [Full Text] [Related]

  • 14. The Phenoxyalkyltriazine Antagonists for 5-HT6 Receptor with Promising Procognitive and Pharmacokinetic Properties In Vivo in Search for a Novel Therapeutic Approach to Dementia Diseases.
    Sudoł S, Cios A, Jastrzębska-Więsek M, Honkisz-Orzechowska E, Mordyl B, Wilczyńska-Zawal N, Satała G, Kucwaj-Brysz K, Partyka A, Latacz G, Olejarz-Maciej A, Wesołowska A, Handzlik J.
    Int J Mol Sci; 2021 Oct 05; 22(19):. PubMed ID: 34639113
    [Abstract] [Full Text] [Related]

  • 15. Predicting biological activity and design of 5-HT6 antagonists through assessment of ANN-QSAR models in the context of Alzheimer's disease.
    de Sousa DS, da Silva AP, Chiari LPA, de Angelo RM, de Sousa AG, Honorio KM, da Silva ABF.
    J Mol Model; 2024 Sep 26; 30(10):350. PubMed ID: 39325274
    [Abstract] [Full Text] [Related]

  • 16. Hydrophobicity modulation via the substituents at positions 2 and 4 of 1,3,5-triazine to enhance therapeutic ability against Alzheimer's disease for potent serotonin 5-HT6R agents.
    Sudoł-Tałaj S, Kucwaj-Brysz K, Podlewska S, Kurczab R, Satała G, Mordyl B, Głuch-Lutwin M, Wilczyńska-Zawal N, Jastrzębska-Więsek M, Czarnota-Łydka K, Kurowska K, Kubacka M, Żesławska E, Nitek W, Olejarz-Maciej A, Doroz-Płonka A, Partyka A, Latacz G, Wesołowska A, Handzlik J.
    Eur J Med Chem; 2023 Nov 15; 260():115756. PubMed ID: 37657272
    [Abstract] [Full Text] [Related]

  • 17. Serotonin: A New Hope in Alzheimer's Disease?
    Claeysen S, Bockaert J, Giannoni P.
    ACS Chem Neurosci; 2015 Jul 15; 6(7):940-3. PubMed ID: 26011650
    [Abstract] [Full Text] [Related]

  • 18. Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer's disease.
    Yahiaoui S, Hamidouche K, Ballandonne C, Davis A, de Oliveira Santos JS, Freret T, Boulouard M, Rochais C, Dallemagne P.
    Eur J Med Chem; 2016 Oct 04; 121():283-293. PubMed ID: 27266998
    [Abstract] [Full Text] [Related]

  • 19. AVN-322 is a Safe Orally Bio-Available Potent and Highly Selective Antagonist of 5-HT6R with Demonstrated Ability to Improve Impaired Memory in Animal Models.
    Ivachtchenko AV, Ivanenkov YA, Veselov MS, Okun IM.
    Curr Alzheimer Res; 2017 Oct 04; 14(3):268-294. PubMed ID: 27829340
    [Abstract] [Full Text] [Related]

  • 20. The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease.
    Geldenhuys WJ, Van der Schyf CJ.
    Expert Rev Neurother; 2009 Jul 04; 9(7):1073-85. PubMed ID: 19589055
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.